TGFB1 and arthritic joint disease: Moreover, increased TGF-β plasma levels as a consequence of either exogenous administration or overexpression protect from experimental inflammatory diseases, including arthritis, autoimmune encephalomyelitis, nonobese diabetic mice, and systemic lupus erythematous [58–60].